Defined Wealth Management LLC Takes $368,000 Position in Becton, Dickinson and Company (NYSE:BDX)

Defined Wealth Management LLC acquired a new position in Becton, Dickinson and Company (NYSE:BDX) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,487 shares of the medical instruments supplier’s stock, valued at approximately $368,000.

Other large investors have also recently bought and sold shares of the company. Ontario Teachers Pension Plan Board increased its stake in shares of Becton, Dickinson and Company by 3.8% during the fourth quarter. Ontario Teachers Pension Plan Board now owns 1,852,278 shares of the medical instruments supplier’s stock valued at $451,641,000 after acquiring an additional 68,509 shares during the period. Sapient Capital LLC acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter valued at $1,295,000. Vest Financial LLC raised its stake in shares of Becton, Dickinson and Company by 27.5% in the 4th quarter. Vest Financial LLC now owns 103,004 shares of the medical instruments supplier’s stock worth $25,115,000 after buying an additional 22,207 shares in the last quarter. Caden Capital Partners LP lifted its holdings in shares of Becton, Dickinson and Company by 26.7% in the fourth quarter. Caden Capital Partners LP now owns 83,417 shares of the medical instruments supplier’s stock valued at $20,340,000 after buying an additional 17,599 shares during the period. Finally, SG Americas Securities LLC boosted its stake in Becton, Dickinson and Company by 69.4% during the fourth quarter. SG Americas Securities LLC now owns 15,113 shares of the medical instruments supplier’s stock valued at $3,685,000 after buying an additional 6,190 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Barclays upped their price target on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a report on Monday, May 6th. The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a research note on Thursday, May 30th. They set a “buy” rating and a $274.00 target price for the company. Finally, StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $280.17.

Becton, Dickinson and Company Stock Down 1.0 %

Shares of NYSE:BDX opened at $231.60 on Thursday. The firm has a 50 day simple moving average of $234.43 and a 200 day simple moving average of $237.93. Becton, Dickinson and Company has a 52 week low of $224.00 and a 52 week high of $287.32. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. The company has a market cap of $66.93 billion, a PE ratio of 51.01, a price-to-earnings-growth ratio of 2.05 and a beta of 0.44.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.20. The company had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The company’s revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.86 EPS. As a group, research analysts expect that Becton, Dickinson and Company will post 13.04 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be given a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.64%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the sale, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, SVP Thomas J. Spoerel sold 300 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the transaction, the senior vice president now owns 1,976 shares in the company, valued at approximately $472,876.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares in the company, valued at $1,252,750.61. The disclosure for this sale can be found here. Insiders sold 8,615 shares of company stock valued at $2,033,381 in the last quarter. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.